CAS 1688703-26-5

Stafib-1

Description:

As of my last update in October 2023, "Stafib-1" with the CAS number 1688703-26-5 is not widely recognized in the scientific literature or databases, indicating it may be a novel compound or a substance under investigation. Typically, compounds with specific CAS numbers are characterized by their molecular structure, functional groups, physical properties (such as melting point, boiling point, solubility), and potential applications in various fields, including pharmaceuticals or materials science. To obtain detailed characteristics, including its chemical formula, reactivity, and safety data, it is advisable to consult specialized chemical databases, peer-reviewed journals, or safety data sheets provided by manufacturers or research institutions. If Stafib-1 is a recent development, further information may be available through ongoing research publications or patent filings.

Formula: C₂₆H₂₄N₂O₁₁P₂

Synonyms:

• STAT,Inhibitor,Stafib-1,STAT5b,inhibit,K562
• Stafib-1

4-((2-((6-(Phenylcarbamoyl)naphthalen-2-yl)oxy)acetamido)methyl)-1,2-phenylene bis(dihydrogen phosphate)

CAS: 1688703-26-5

4-((2-((6-(Phenylcarbamoyl)naphthalen-2-yl)oxy)acetamido)methyl)-1,2-phenylene bis(dihydrogen phosphate)

Purity: 99%

Molecular weight: 602.43g/mol

Ref: 54-OR1065242

Stafib-1

CAS: 1688703-26-5

Stafib-1 is a selective inhibitor of STAT5β targeting SH2 domain with an IC50 of 154 nM and a Ki of 44 nM.

Formula: C₂₆H₂₄N₂O₁₁P₂

Purity: 97.18%

Color and Shape: Solid

Molecular weight: 602.42

Ref: TM-T24838

[4-[[[2-[6-(Phenylcarbamoyl)naphthalen-2-yl]oxyacetyl]amino]methyl]-2-phosphonooxyphenyl] dihydrogen phosphate

CAS: 1688703-26-5

Nilotinib is a tyrosine kinase inhibitor that is used to treat chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. It is also being studied for use in the treatment of other cancers, including breast cancer and gastrointestinal stromal tumor. Nilotinib inhibits the activity of tyrosine kinases, which are enzymes that regulate cellular processes such as cell division and differentiation. This effect causes cells to stop dividing or die. Nilotinib has been shown to be effective against chronic myeloid leukemia by inhibiting BCR-ABL, the protein associated with this disease, as well as other tyrosine kinases involved in cancer progression. The drug has proven successful in clinical trials involving patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. In addition, nilotinib has been shown to inhibit the constitutive activation of c-KIT, a receptor tyrosine kinase that is overexpressed in certain types of

Formula: C₂₆H₂₄N₂O₁₁P₂

Purity: Min. 95%

Molecular weight: 602.4 g/mol

Ref: 3D-NSC70326